← back to search

Val Gebski

Centre de recherche en Epidémiologie et Santé des Populations · FR
🔎 Find collaborators in Oncology · Reproductive Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Reproductive Medicine
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, Breast Cancer Treatment Studies, and Colorectal Cancer Treatments and Studies.
h-index
88
citations
35,542
works
751
NIH funding
primary concept
email

Recent publications

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
Nature Medicine 2025cited by 27position: middledoi
Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk model.
2025cited by 3position: contributordoi
Under the radar-frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies.
2025cited by 0position: contributordoi
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer
Journal of Clinical Oncology 2024cited by 75position: middledoi
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.
2024cited by 56position: contributordoi
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology 2024cited by 21position: middledoi
Australian radiation therapist's research capacity and culture: investigating the extent of assistance required to build research capacity.
2024cited by 1position: contributordoi
Feasibility and safety of a surgical training program in total laparoscopic hysterectomy: Results of a pilot trial.
2024cited by 1position: contributordoi
Effect of a correlated competing risk on marginal survival estimation in an accelerated failure time model
Communications in Statistics - Simulation and Computation 2024cited by 0position: contributordoi
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
The Lancet Oncology 2023cited by 185position: middledoi
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
The Lancet 2023cited by 57position: middledoi
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
Journal of Clinical Oncology 2023cited by 37position: middledoi
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
Brain 2023cited by 32position: middledoi
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
BMC Cancer 2023cited by 28position: middledoi
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
2023cited by 26position: contributordoi
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.
2023cited by 22position: contributordoi
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
British Journal of Cancer 2023cited by 6position: middledoi
Groin Surveillance by Serial Ultrasonography Rather Than Sentinel Node Biopsy or Inguinofemoral Lymphadenectomy for Patients with Vulvar Cancer: A Pilot Study.
2023cited by 3position: contributordoi
Improving efficiency of fitting Cox proportional hazards models for time-to-event outcomes in genome-wide association studies (GWAS).
2023cited by 1position: contributordoi
Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer.
2023cited by 0position: contributordoi
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology 2022cited by 139position: middledoi
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study
The Lancet Oncology 2022cited by 83position: middledoi
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.
2022cited by 55position: contributordoi
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
Annals of Oncology 2022cited by 27position: middledoi
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial.
2022cited by 25position: contributordoi
Patient-Reported Bowel, Urinary, and Sexual Outcomes After Laparoscopic-Assisted Resection or Open Resection for Rectal Cancer
Annals of Surgery 2022cited by 20position: middledoi
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
2022cited by 16position: contributordoi
Neurodevelopmental outcomes of preterm infants after randomisation to initial resuscitation with lower (FiO<sub>2</sub> <u><</u>0.3) or higher (FiO<sub>2</sub> <u>></u>0.6) initial oxygen levels. An individual patient meta-analysis.
2022cited by 12position: contributordoi
Combination chemotherapy with NAB<sup>®</sup> -paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study).
2022cited by 10position: contributordoi
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
2022cited by 10position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2021–2025)Chee Khoon Lee · Liverpool Hospital12 papers (2013–2023)John Simes · Respiratory Clinical Trials11 papers (2019–2025)Andreas Obermair · The University of Queensland11 papers (2018–2024)Kate Wilson · Nuffield Health7 papers (2013–2022)Monika Janda · Queensland Health7 papers (2019–2024)Éric Pujade-Lauraine · Hospital Universitario Ramón y Cajal7 papers (2014–2023)John Simes · Chris O’Brien Lifehouse7 papers (2015–2021)Andrew P. Barbour · Metro South Health7 papers (2020–2023)Kristy Robledo · The University of Sydney6 papers (2018–2024)David J. Handelsman · Concord Hospital6 papers (2019–2025)James Chih‐Hsin Yang · National Institutes of Health6 papers (2013–2017)Sarah J. Lord · The University of Notre Dame Australia6 papers (2020–2025)Richard J. Gralla · Albert Einstein College of Medicine5 papers (2013–2017)Wendy Hague · The University of Sydney5 papers (2015–2023)Chris Brown · Children's Hospital of Philadelphia5 papers (2012–2019) · 5 papers (2019–2024)Bu B Yeap · Ferdowsi University of Mashhad5 papers (2019–2025)Bronwyn G. A. Stuckey · Human Growth Foundation5 papers (2019–2025)Alicia Jenkins · Equilibrium Research5 papers (2019–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Reproductive Medicine →